Question 1

How does retatrutide differ from tirzepatide?

Accepted Answer

Retatrutide adds glucagon receptor agonism on top of GLP-1 and GIP. The glucagon component increases energy expenditure and fat oxidation beyond what dual agonists achieve.

Question 2

Is retatrutide FDA-approved?

Accepted Answer

Not yet. It is in Phase 3 clinical trials with results expected in 2025-2026.

Question 3

Why add glucagon if it raises blood sugar?

Accepted Answer

The GLP-1 component offsets glucagon's glycemic effect, while glucagon's metabolic benefits (increased energy expenditure, hepatic fat reduction) add to the overall effect.

What is Retatrutide - Peptide Encyclopedia